Bleeding, recurrent venous thromboembolism, and mortality risks duringwarfarin interruption for invasive procedures

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1163-1168

  Clark, Nathan P ^a,b   Witt, Daniel M ^a,c   Davies, Loren E ^a,d   Saito, Edward M ^a,e   McCool, Kathleen H ^a,b   Douketis, James D ^f   Metz, Kelli R ^b,g   Delate, Thomas ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^e PACIFIC UNIVERSITY   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g State of Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEMATOMA; HIGH RISK PATIENT; HUMAN; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MORTALITY; PRIORITY JOURNAL; RECTUS SHEATH HEMATOMA; RECURRENT DISEASE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPARATIVE STUDY; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDY; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COLORADO; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84937468318     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1843     Document Type: Article

References (13)

1. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1):63-69.
2. Douketis JD, Spyropoulos AC, Spencer FA, et al; American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e326S-e350S. doi:10.1378/chest.11-2298.
3. Birnie DH, Healey JS,Wells GA, et al; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084-2093.
4. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004; 164(12):1319-1326.
5. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5(11):2211-2218.
6. Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med. 2010;123(2): 141-150.
7. KovacsMJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecularweight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004;110(12):1658-1663.
8. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127(5):1515-1522.
9. Spyropoulos AC, Douketis JD, Gerotziafas G, Kaatz S, Ortel TL, Schulman S; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012;10(4):692-694.
10. Schulman S, Anger?s U, Bergqvist D, Eriksson B, Lassen MR, FisherW; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202-204.
11. McBane RD,Wysokinski WE, Daniels PR, et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30(3):442-448.
12. Skeith L, Taylor J, Lazo-Langner A, Kovacs MJ. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. J Thromb Haemost. 2012;10(11):2298-2304.
13. Siegal D, Yudin J, Kaatz S, Douketis JD, LimW, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13): 1630-1639.